A detailed history of Advisors Asset Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Advisors Asset Management, Inc. holds 6,696 shares of BIIB stock, worth $1.08 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,696
Previous 6,549 2.24%
Holding current value
$1.08 Million
Previous $1.52 Million 14.56%
% of portfolio
0.02%
Previous 0.03%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$189.07 - $236.8 $27,793 - $34,809
147 Added 2.24%
6,696 $1.3 Million
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $169,943 - $211,154
-892 Reduced 11.99%
6,549 $1.52 Million
Q1 2024

May 14, 2024

BUY
$212.02 - $267.71 $95,621 - $120,737
451 Added 6.45%
7,441 $1.6 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $245,739 - $295,805
1,104 Added 18.76%
6,990 $1.81 Million
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $157,443 - $181,930
572 Added 10.76%
5,886 $1.68 Million
Q1 2023

May 12, 2023

SELL
$256.56 - $292.34 $40,536 - $46,189
-158 Reduced 2.89%
5,314 $1.48 Million
Q3 2022

Nov 08, 2022

BUY
$194.69 - $268.46 $65,221 - $89,934
335 Added 6.24%
5,706 $1.52 Million
Q2 2022

Aug 08, 2022

BUY
$187.54 - $223.02 $187,164 - $222,573
998 Added 22.82%
5,371 $1.1 Million
Q1 2022

May 17, 2022

SELL
$193.77 - $244.14 $176,524 - $222,411
-911 Reduced 17.24%
4,373 $921,000
Q4 2021

Feb 15, 2022

BUY
$223.92 - $287.77 $52,845 - $67,913
236 Added 4.68%
5,284 $1.27 Million
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $15,564 - $20,297
55 Added 1.1%
5,048 $1.43 Million
Q2 2021

Jul 30, 2021

BUY
$259.0 - $414.71 $131,313 - $210,257
507 Added 11.3%
4,993 $1.73 Million
Q1 2021

May 07, 2021

BUY
$242.95 - $284.63 $330,412 - $387,096
1,360 Added 43.51%
4,486 $1.26 Million
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $345,412 - $519,931
1,462 Added 87.86%
3,126 $765,000
Q3 2020

Nov 16, 2020

BUY
$264.77 - $305.71 $20,122 - $23,233
76 Added 4.79%
1,664 $472,000
Q2 2020

Aug 12, 2020

SELL
$258.66 - $342.55 $94,669 - $125,373
-366 Reduced 18.73%
1,588 $425,000
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $131,198 - $166,427
-488 Reduced 19.98%
1,954 $618,000
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $125,434 - $173,319
-570 Reduced 18.92%
2,442 $725,000
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $325,290 - $364,844
-1,496 Reduced 33.19%
3,012 $701,000
Q2 2019

Aug 14, 2019

SELL
$219.29 - $241.72 $128,284 - $141,406
-585 Reduced 11.49%
4,508 $1.05 Million
Q1 2019

May 15, 2019

SELL
$216.71 - $338.96 $278,905 - $436,241
-1,287 Reduced 20.17%
5,093 $1.2 Million
Q4 2018

Jan 31, 2019

SELL
$278.5 - $352.75 $2.2 Million - $2.78 Million
-7,887 Reduced 55.28%
6,380 $1.92 Million
Q3 2018

Nov 15, 2018

SELL
$293.51 - $383.83 $243,319 - $318,195
-829 Reduced 5.49%
14,267 $5.04 Million
Q2 2018

Aug 15, 2018

BUY
$257.52 - $306.91 $287,134 - $342,204
1,115 Added 7.98%
15,096 $4.38 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $46,563 - $65,855
179 Added 1.3%
13,981 $4.03 Million
Q4 2017

Feb 13, 2018

BUY
$307.64 - $344.58 $143,052 - $160,229
465 Added 3.49%
13,802 $4.4 Million
Q3 2017

Nov 07, 2017

BUY
$281.15 - $329.69 $3.75 Million - $4.4 Million
13,337
13,337 $4.18 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $23.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.